Cell Signaling and Developmental Pharmacology

细胞信号和发育药理学计划的研究重点是信号通路 以及它们对癌症进展、治疗和并发症管理的影响。总体目标 该计划的成员之一是了解恶性细胞中的基本细胞信号事件和 将这一认识应用于开发新的药物或新的治疗方案 癌症的威胁。该计划的研究有两个主题。 主题1-了解调节恶性细胞行为的基本细胞信号事件 主题2-新药或新药组合的翻译和临床试验 细胞信号和发育药理学项目的研究人员已经做出了一些 具有重大临床意义的发现。例如，他们对(A)作出了重大贡献 甲氧丙酮酸-胆固醇途径中类异戊二烯中间体如何调节的认识 RAS和RAS相关小GTP酶的表达，(B)双吲哚马来酰亚胺IX可以覆盖 Bcl-2和(C)研究探索多种肿瘤的创新临床治疗方案 癌症。过去和现在都有许多富有成效的合作， 计划，以及其他癌症中心计划的成员。细胞信号与发育 药理学专业由来自4所学院17个系的38名成员组成。同行评议，直接 该项目的研究资金总额为3,825,705美元，其中1,213,571美元来自NCI。

Research in the Cell Signaling and Developmental Pharmacology Program focuses on signaling pathways and how they impact on cancer progression, therapy and management of complications. The overall goals of the members of this program are to understand fundamental cell signaling events in malignant cells and apply this understanding to the development of new agents or novel therapeutic regimens for the treatment of cancer. There are two themes within the Program's research. Theme 1 - Understanding fundamental cell signaling events that regulate malignant cell behavior Theme 2 - Translational and clinical trials of novel agents or novel combinations of agents Investigators in the Cell Signaling and Developmental Pharmacology Program have made a number of discoveries that have significant clinical implications. For example, they have contributed significantly to (a) our understanding of how isoprenoid intermediates in the mevalonic acid to cholesterol pathway regulate expression of RAS and RAS-related small GTPases, (b) that bisindoylmalemimide IX can override the apoptosis-inhibitory effects of Bcl-2 and (c) studies exploring innovative clinical regimens for a variety of cancers. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. The Cell Signaling and Developmental Pharmacology Program consists of 38 members from 17 departments in 4 colleges. Peer-reviewed, direct research funding for this program totals $3,825,705, with $1,213,571 of this support coming from the NCI.